GSC
CATX icon

Ground Swell Capital’s Perspective Therapeutics CATX Stock Holding History

Ground Swell Capital’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,373
Closed -$56.3K – 150
2025
Q2 		$56.3K Buy
+16,373
New +$43.2K 0.09% 69

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $172M AUM 10.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ground Swell Capital's CATX Position: Q3 2025 in Review

Ground Swell Capital sold out of Perspective Therapeutics (CATX) in Q3 2025, closing a stake of 16,373 shares — an estimated $56.3K sold.

Ground Swell Capital first reported a position in CATX in Q2 2025 and held it in 1 quarter. The position peaked at $56.3K in Q2 2025. 105 funds tracked by Wall St. Rank hold CATX as of Q3 2025.

  • Ground Swell Capital reported no remaining Perspective Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Ground Swell Capital sold 16,373 Perspective Therapeutics shares in Q3 2025, an estimated $56.3K.
  • Ground Swell Capital first reported a position in Perspective Therapeutics in Q2 2025 and held it in 1 quarter.
  • Ground Swell Capital's Perspective Therapeutics position peaked at $56.3K in Q2 2025.
  • 105 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2025.

Based on Ground Swell Capital's 13F filing for Q3 2025, filed 6 Nov 2025.